Skip to main content
Erschienen in: Strahlentherapie und Onkologie 3/2023

09.11.2022 | Original Article

Traditional risk factors and nodal yield—still relevant with high-quality risk-adapted adjuvant treatment for locally advanced head and neck cancer?

verfasst von: Y. Butt, P. Tennstedt, C.-J. Busch, H. Hanken, A. Krüll, C. Petersen, S. Tribius, MD PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Patients with locally advanced head and neck cancer (LAHNC) often undergo multimodal therapy including radical resection of the primary tumor and neck dissection (ND) followed by risk-adapted adjuvant radio(chemo)therapy (R(C)T). Quality parameters influencing local control and survival of these patients have been postulated: resection status (R status), extranodal extension (ENE), interval to adjuvant treatment ≤6 weeks, R(C)T given when indicated, and nodal yield (NY) ≥18 lymph nodes per neck. For other solid tumors the trend is towards less extensive lymph node surgery to avoid toxicity such as lymphedema, damage to peripheral nerves, dysesthesia, or paresthesia. The present study aims to investigate whether the number of nodes removed during neck dissection for LAHNC is still predictive for outcome when patients receive risk-adapted adjuvant treatment according to current guidelines.

Methods

Between 2008 and 2015, 468 patients with LAHNC undergoing R(C)T with curative intent were prospectively registered in a database (UICC III/IV). Among them, 359 patients received adjuvant treatment and 295 underwent neck dissection. There were 119 (40%) patients with an oropharyngeal primary, 49 (17%) with cancer of the larynx/hypopharynx, 88 (30%) of the oral cavity, and 39 (13%) of the nasal/paranasal sinuses and cancer of unknown primary (CUP). Median follow-up was 45.6 months. Histopathology revealed an R1 status in 65 (22%) cases and ENE in 93 (31%) cases. 150 (51%) patients received RCT; the median time to adjuvant treatment from the day of tumor resection was 44 days (35–54) and overall treatment time (OTT; time from surgery to the last day of R(C)T) was 90 days (82–101). Factors influencing disease-free survival (DFS) were adjusted and analyzed using CART analysis (removed nodes, number of positive nodes, body mass index (BMI), ENE, T and N classification, R status, and primary site). Local control (LC), distant metastases-free survival (DMFS), and overall survival (OS) were analyzed using Kaplan–Meier statistics and multivariate analysis (MVA) for factors predictive for DFS and OS.

Results

CART analysis (Classification and Regression Trees) showed that T classification (T3/4) is the most important predictor for DFS, followed by age (> 61 years) and BMI (< 17.4). Primary site (OPC vs. other) and number of removed nodes (< 17) were shown to be less important for DFS, while ECE, N classification, and R status seem to be of little relevance. MVA revealed number of positive nodes, non-OPC, and T3/4 to be negative predictive factors for DFS. For OS, the number of positive nodes and non-OPC primary were predictive. Five-year rates were 86.1% for LC, 87.9% DMFS, 76.5% DFS, and 67.2% for OS.

Conclusion

In this patient cohort, the number of removed nodes is not relevant for DFS and OS, while the number of positive nodes and T classification have a negative impact on these endpoints. The high-risk factors positive resection margin and ECE seem to lose their negative impact on DFS and OS. High-quality care in head and oncology is only possible within a close multidisciplinary team and network.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef
3.
Zurück zum Zitat Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850PubMedCrossRef Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850PubMedCrossRef
4.
Zurück zum Zitat Heiduschka G, Grah A, Oberndorfer F, Kadletz L, Altorjai G, Kornek G et al (2015) Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191(3):209–216PubMedCrossRef Heiduschka G, Grah A, Oberndorfer F, Kadletz L, Altorjai G, Kornek G et al (2015) Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191(3):209–216PubMedCrossRef
5.
Zurück zum Zitat Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35PubMedPubMedCentralCrossRef Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Tribius S, Raguse M, Voigt C, Munscher A, Grobe A, Petersen C et al (2015) Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: results of a prospective study. Strahlenther Onkol 191(6):501–510PubMedCrossRef Tribius S, Raguse M, Voigt C, Munscher A, Grobe A, Petersen C et al (2015) Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: results of a prospective study. Strahlenther Onkol 191(6):501–510PubMedCrossRef
7.
Zurück zum Zitat Deng J, Sinard RJ, Murphy B (2019) Patient experience of head and neck lymphedema therapy: a qualitative study. Support Care Cancer 27(5):1811–1823PubMedCrossRef Deng J, Sinard RJ, Murphy B (2019) Patient experience of head and neck lymphedema therapy: a qualitative study. Support Care Cancer 27(5):1811–1823PubMedCrossRef
8.
Zurück zum Zitat McGarvey AC, Osmotherly PG, Hoffman GR, Chiarelli PE (2014) Lymphoedema following treatment for head and neck cancer: impact on patients, and beliefs of health professionals. Eur J Cancer Care (Engl) 23(3):317–327PubMedCrossRef McGarvey AC, Osmotherly PG, Hoffman GR, Chiarelli PE (2014) Lymphoedema following treatment for head and neck cancer: impact on patients, and beliefs of health professionals. Eur J Cancer Care (Engl) 23(3):317–327PubMedCrossRef
9.
Zurück zum Zitat Cramer JD, Speedy SE, Ferris RL, Rademaker AW, Patel UA, Samant S (2017) National evaluation of multidisciplinary quality metrics for head and neck cancer. Cancer 123(22):4372–4381PubMedCrossRef Cramer JD, Speedy SE, Ferris RL, Rademaker AW, Patel UA, Samant S (2017) National evaluation of multidisciplinary quality metrics for head and neck cancer. Cancer 123(22):4372–4381PubMedCrossRef
10.
Zurück zum Zitat Tribius S, Donner J, Pazdyka H, Munscher A, Grobe A, Petersen C et al (2016) Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. Head Neck 38(7):1058–1065PubMedCrossRef Tribius S, Donner J, Pazdyka H, Munscher A, Grobe A, Petersen C et al (2016) Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. Head Neck 38(7):1058–1065PubMedCrossRef
11.
Zurück zum Zitat Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84(5):1198–1205PubMedPubMedCentralCrossRef Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84(5):1198–1205PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Kuhnt T, Klockenbrink U, Knipping S, Lautermann J, Kriese K, Wienke A et al (2011) Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases. Strahlenther Onkol 187(5):292–299PubMedCrossRef Kuhnt T, Klockenbrink U, Knipping S, Lautermann J, Kriese K, Wienke A et al (2011) Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases. Strahlenther Onkol 187(5):292–299PubMedCrossRef
13.
Zurück zum Zitat Agrama MT, Reiter D, Cunnane MF, Topham A, Keane WM (2003) Nodal yield in neck dissection and the likelihood of metastases. Otolaryngol Head Neck Surg 128(2):185–190PubMedCrossRef Agrama MT, Reiter D, Cunnane MF, Topham A, Keane WM (2003) Nodal yield in neck dissection and the likelihood of metastases. Otolaryngol Head Neck Surg 128(2):185–190PubMedCrossRef
14.
Zurück zum Zitat Goldstein NS (2002) Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol 26(2):179–189PubMedCrossRef Goldstein NS (2002) Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol 26(2):179–189PubMedCrossRef
15.
Zurück zum Zitat Shrime MG, Bachar G, Lea J, Volling C, Ma C, Gullane PJ et al (2009) Nodal ratio as an independent predictor of survival in squamous cell carcinoma of the oral cavity. Head Neck 31(11):1482–1488PubMedCrossRef Shrime MG, Bachar G, Lea J, Volling C, Ma C, Gullane PJ et al (2009) Nodal ratio as an independent predictor of survival in squamous cell carcinoma of the oral cavity. Head Neck 31(11):1482–1488PubMedCrossRef
16.
Zurück zum Zitat Rudoltz MS, Benammar A, Mohiuddin M (1995) Does pathologic node status affect local control in patients with carcinoma of the head and neck treated with radical surgery and postoperative radiotherapy? Int J Radiat Oncol Biol Phys 31(3):503–508PubMedCrossRef Rudoltz MS, Benammar A, Mohiuddin M (1995) Does pathologic node status affect local control in patients with carcinoma of the head and neck treated with radical surgery and postoperative radiotherapy? Int J Radiat Oncol Biol Phys 31(3):503–508PubMedCrossRef
17.
Zurück zum Zitat Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR (1997) An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys 39(1):137–148PubMedCrossRef Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR (1997) An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys 39(1):137–148PubMedCrossRef
18.
Zurück zum Zitat Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V (2016) Number of positive nodes is superior to the lymph node ratio and American joint committee on cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas. Cancer 122(9):1388–1397PubMedCrossRef Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V (2016) Number of positive nodes is superior to the lymph node ratio and American joint committee on cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas. Cancer 122(9):1388–1397PubMedCrossRef
19.
Zurück zum Zitat Gleisner AL, Mogal H, Dodson R, Efron J, Gearhart S, Wick E et al (2013) Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma? J Am Coll Surg 217(6):1090–1100PubMedCrossRef Gleisner AL, Mogal H, Dodson R, Efron J, Gearhart S, Wick E et al (2013) Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma? J Am Coll Surg 217(6):1090–1100PubMedCrossRef
21.
Zurück zum Zitat Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952PubMedCrossRef Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952PubMedCrossRef
23.
Zurück zum Zitat Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346PubMedCrossRef Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346PubMedCrossRef
24.
Zurück zum Zitat Team RC (2020) R: a language and environment for statistical computing. R Foundation for Statistica Computing, Vienna, Austria Team RC (2020) R: a language and environment for statistical computing. R Foundation for Statistica Computing, Vienna, Austria
25.
Zurück zum Zitat Coskun HH, Medina JE, Robbins KT, Silver CE, Strojan P, Teymoortash A et al (2015) Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma. Head Neck 37(6):915–926PubMedCrossRef Coskun HH, Medina JE, Robbins KT, Silver CE, Strojan P, Teymoortash A et al (2015) Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma. Head Neck 37(6):915–926PubMedCrossRef
26.
Zurück zum Zitat Shrime MG, Ma C, Gullane PJ, Gilbert RW, Irish JC, Brown DH et al (2009) Impact of nodal ratio on survival in squamous cell carcinoma of the oral cavity. Head Neck 31(9):1129–1136PubMedCrossRef Shrime MG, Ma C, Gullane PJ, Gilbert RW, Irish JC, Brown DH et al (2009) Impact of nodal ratio on survival in squamous cell carcinoma of the oral cavity. Head Neck 31(9):1129–1136PubMedCrossRef
27.
Zurück zum Zitat Spoerl S, Gerken M, Mamilos A, Fischer R, Wolf S, Nieberle F et al (2021) Lymph node ratio as a predictor for outcome in oral squamous cell carcinoma: a multicenter population-based cohort study. Clin Oral Investig 25(4):1705–1713PubMedCrossRef Spoerl S, Gerken M, Mamilos A, Fischer R, Wolf S, Nieberle F et al (2021) Lymph node ratio as a predictor for outcome in oral squamous cell carcinoma: a multicenter population-based cohort study. Clin Oral Investig 25(4):1705–1713PubMedCrossRef
28.
Zurück zum Zitat Yildiz MM, Petersen I, Eigendorff E, Schlattmann P, Guntinas-Lichius O (2016) Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds? J Cancer Res Clin Oncol 142(4):885–893PubMedCrossRef Yildiz MM, Petersen I, Eigendorff E, Schlattmann P, Guntinas-Lichius O (2016) Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds? J Cancer Res Clin Oncol 142(4):885–893PubMedCrossRef
30.
Zurück zum Zitat Tribius S, Pazdyka H, Tennstedt P, Busch CJ, Hanken H, Krull A et al (2020) Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy-results of a longitudinal study. Oral Oncol 109:104856PubMedCrossRef Tribius S, Pazdyka H, Tennstedt P, Busch CJ, Hanken H, Krull A et al (2020) Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy-results of a longitudinal study. Oral Oncol 109:104856PubMedCrossRef
31.
Zurück zum Zitat Qiu SQ, Zhang GJ, Jansen L, de Vries J, Schroder CP, de Vries EGE et al (2018) Evolution in sentinel lymph node biopsy in breast cancer. Crit Rev Oncol Hematol 123:83–94PubMedCrossRef Qiu SQ, Zhang GJ, Jansen L, de Vries J, Schroder CP, de Vries EGE et al (2018) Evolution in sentinel lymph node biopsy in breast cancer. Crit Rev Oncol Hematol 123:83–94PubMedCrossRef
32.
Zurück zum Zitat Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C et al (2019) Final analysis of deCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 37(32):3000–3008PubMedCrossRef Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C et al (2019) Final analysis of deCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 37(32):3000–3008PubMedCrossRef
33.
Zurück zum Zitat Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26(6):884–889PubMedCrossRef Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26(6):884–889PubMedCrossRef
34.
Zurück zum Zitat Crocetta FM, Botti C, Pernice C, Murri D, Castellucci A, Menichetti M et al (2020) Sentinel node biopsy versus elective neck dissection in early-stage oral cancer: a systematic review. Eur Arch Otorhinolaryngol 277(12):3247–3260PubMedCrossRef Crocetta FM, Botti C, Pernice C, Murri D, Castellucci A, Menichetti M et al (2020) Sentinel node biopsy versus elective neck dissection in early-stage oral cancer: a systematic review. Eur Arch Otorhinolaryngol 277(12):3247–3260PubMedCrossRef
35.
Zurück zum Zitat Garrel R, Poissonnet G, Moya Plana A, Fakhry N, Dolivet G, Lallemant B et al (2020) Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. J Clin Oncol 38(34):4010–4018PubMedCrossRef Garrel R, Poissonnet G, Moya Plana A, Fakhry N, Dolivet G, Lallemant B et al (2020) Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer. J Clin Oncol 38(34):4010–4018PubMedCrossRef
36.
Zurück zum Zitat Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA et al (2015) Sentinel European node trial (SENT): 3‑year results of sentinel node biopsy in oral cancer. Eur J Cancer 51(18):2777–2784PubMedCrossRef Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA et al (2015) Sentinel European node trial (SENT): 3‑year results of sentinel node biopsy in oral cancer. Eur J Cancer 51(18):2777–2784PubMedCrossRef
38.
Zurück zum Zitat Kiricuta IC (2000) Sentinel node concept in breast cancer. Strahlenther Onkol 176(7):307–314PubMedCrossRef Kiricuta IC (2000) Sentinel node concept in breast cancer. Strahlenther Onkol 176(7):307–314PubMedCrossRef
39.
Zurück zum Zitat Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944PubMedCrossRef Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944PubMedCrossRef
40.
Zurück zum Zitat Divi V, Chen MM, Nussenbaum B, Rhoads KF, Sirjani DB, Holsinger FC et al (2016) Lymph node count from neck dissection predicts mortality in head and neck cancer. J Clin Oncol 34(32):3892–3897PubMedCrossRef Divi V, Chen MM, Nussenbaum B, Rhoads KF, Sirjani DB, Holsinger FC et al (2016) Lymph node count from neck dissection predicts mortality in head and neck cancer. J Clin Oncol 34(32):3892–3897PubMedCrossRef
41.
Zurück zum Zitat Ebrahimi A, Clark JR, Amit M, Yen TC, Liao CT, Kowalski LP et al (2014) Minimum nodal yield in oral squamous cell carcinoma: defining the standard of care in a multicenter international pooled validation study. Ann Surg Oncol 21(9):3049–3055PubMedCrossRef Ebrahimi A, Clark JR, Amit M, Yen TC, Liao CT, Kowalski LP et al (2014) Minimum nodal yield in oral squamous cell carcinoma: defining the standard of care in a multicenter international pooled validation study. Ann Surg Oncol 21(9):3049–3055PubMedCrossRef
42.
Zurück zum Zitat Patel SG, Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP et al (2013) Lymph node density in oral cavity cancer: results of the international consortium for outcomes research. Br J Cancer 109(8):2087–2095PubMedPubMedCentralCrossRef Patel SG, Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP et al (2013) Lymph node density in oral cavity cancer: results of the international consortium for outcomes research. Br J Cancer 109(8):2087–2095PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Pou JD, Barton BM, Lawlor CM, Frederick CH, Moore BA, Hasney CP (2017) Minimum lymph node yield in elective level I–III neck dissection. Laryngoscope 127(9):2070–2073PubMedCrossRef Pou JD, Barton BM, Lawlor CM, Frederick CH, Moore BA, Hasney CP (2017) Minimum lymph node yield in elective level I–III neck dissection. Laryngoscope 127(9):2070–2073PubMedCrossRef
44.
Zurück zum Zitat Ebrahimi A, Zhang WJ, Gao K, Clark JR (2011) Nodal yield and survival in oral squamous cancer: defining the standard of care. Cancer 117(13):2917–2925PubMedCrossRef Ebrahimi A, Zhang WJ, Gao K, Clark JR (2011) Nodal yield and survival in oral squamous cancer: defining the standard of care. Cancer 117(13):2917–2925PubMedCrossRef
45.
Zurück zum Zitat Clark JR, Naranjo N, Franklin JH, de Almeida J, Gullane PJ (2006) Established prognostic variables in N0 oral carcinoma. Otolaryngol Head Neck Surg 135(5):748–753PubMedCrossRef Clark JR, Naranjo N, Franklin JH, de Almeida J, Gullane PJ (2006) Established prognostic variables in N0 oral carcinoma. Otolaryngol Head Neck Surg 135(5):748–753PubMedCrossRef
46.
Zurück zum Zitat Le Tourneau C, Jung GM, Borel C, Bronner G, Flesch H, Velten M (2008) Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. Acta Otolaryngol 128(6):706–712PubMedCrossRef Le Tourneau C, Jung GM, Borel C, Bronner G, Flesch H, Velten M (2008) Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. Acta Otolaryngol 128(6):706–712PubMedCrossRef
47.
Zurück zum Zitat Guttmann DM, Kobie J, Grover S, Lin A, Lukens JN, Mitra N et al (2018) National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival. Head Neck 40(6):1147–1155PubMedCrossRef Guttmann DM, Kobie J, Grover S, Lin A, Lukens JN, Mitra N et al (2018) National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival. Head Neck 40(6):1147–1155PubMedCrossRef
48.
Zurück zum Zitat Rosenthal DI, Liu L, Lee JH, Vapiwala N, Chalian AA, Weinstein GS et al (2002) Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck 24(2):115–126PubMedCrossRef Rosenthal DI, Liu L, Lee JH, Vapiwala N, Chalian AA, Weinstein GS et al (2002) Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck 24(2):115–126PubMedCrossRef
49.
Zurück zum Zitat Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J et al (2010) Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 28(18):2996–3001PubMedCrossRef Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J et al (2010) Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 28(18):2996–3001PubMedCrossRef
50.
Zurück zum Zitat Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A et al (2015) Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33(2):156–164PubMedCrossRef Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A et al (2015) Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33(2):156–164PubMedCrossRef
Metadaten
Titel
Traditional risk factors and nodal yield—still relevant with high-quality risk-adapted adjuvant treatment for locally advanced head and neck cancer?
verfasst von
Y. Butt
P. Tennstedt
C.-J. Busch
H. Hanken
A. Krüll
C. Petersen
S. Tribius, MD PhD
Publikationsdatum
09.11.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 3/2023
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-02017-x

Weitere Artikel der Ausgabe 3/2023

Strahlentherapie und Onkologie 3/2023 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.